Please assess the completion status of the following clinical trial:

Trial Title: Docetaxel, Androgen Deprivation and Proton Therapy for High Risk Prostate Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~\* Adenocarcinoma of the prostate.~Exclusion Criteria:~* Previous prostate cancer treatment such as chemotherapy and/or pelvic radiation.~* Active inflammatory bowel disease (diverticulitis, Crohn's disease or ulcerative colitis) affecting the rectum. (Non-active diverticulitis and Crohn's disease not affecting the rectum are allowed.)~* History of hip replacement.~* Prior intrapelvic surgery. This includes the following:~* Transrectal or rectal surgery other than polypectomy or hemorrhoid removal or banding~* Transabdominal pelvic surgery~* Bladder surgery~* Prior myocardial infarction (MI) or congestive heart failure (CHF).~* Taking Saw Palmetto or methotrexate and unable or unwilling to discontinue its use during radiation.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- High-risk arm A (HR-A) (Type: EXPERIMENTAL): \< 15% risk of + lymph nodes (LN)
- HR-B (Type: EXPERIMENTAL): \> 15% risk of + LN

Based on this trial design, predict the completion outcome and termination type (if applicable).